Facebook Twitter LinkedIn Google Plus RSS

PTC Therapeutics appoints chief commercial officer

By ,

South Plainfield-based PTC Therapeutics, Inc. announced Tuesday the appointment of Mark A. Rothera as chief commercial officer, responsible for global commercial functions supporting PTC's pipeline, including the investigational new drug ataluren.

A veteran of the orphan drug arena, Mr. Rothera has spent 15 of his 23 years in the biopharmaceutical industry, according to a release. He served previously as global president of Aegerion Pharmaceuticals Inc.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!